A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas.

Glob Reg Health Technol Assess · 2024 · PMC10788683 · PMID 38230389

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

The costs are characterized by a decreasing trend since the fifth year of treatment, settling at a cost of €1,014.07 ( Supplementary Table 20-24 ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.